Risk of marrow neoplasms after adjuvant breast cancer therapy: The national comprehensive cancer network experien

Journal of Clinical Oncology

Volumn 33, Issue 4, 2015, Pages 340-348

  Wolff, Antonio C ^a   Blackford, Amanda L ^a   Visvanathan, Kala ^a   Rugo, Hope S ^b   Moy, Beverly ^c   Goldstein, Lori J ^e   Stockerl Goldstein, Keith ^f   Neumayer, Leigh ^g   Langbaum, Terry S ^a   Theriault, Richard L ^h   Hughes, Melissa E ^d   Weeks, Jane C ^d   Karp, Judith E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BONE MARROW CANCER; BREAST CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOGENETICS; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; RACE; ADOLESCENT; ADVERSE EFFECTS; AGED; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; CANCER REGISTRY; CLASSIFICATION; COHORT ANALYSIS; FACTUAL DATABASE; FEMALE; FOLLOW UP; INCIDENCE; MASTECTOMY; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; RADIOTHERAPY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); RADIOTHERAPY; RISK FACTORS; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84921928861     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.6119     Document Type: Article

References (21)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432-444, 2012
2. Shapiro CL, Recht A: Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997-2008, 2001
3. Curtis RE, Boice JD Jr, Stovall M, et al: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326: 1745-1751, 1992
4. Smith RE, Bryant J, DeCillis A, et al: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21:1195-1204, 2003
5. Golomb HM, Alimena G, Rowley JD, et al: Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood 60:404-411, 1982
6. West RR, Stafford DA, White AD, et al: Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood 95: 2093-2097, 2000
7. Martin MG, Welch JS, Luo J, et al: Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat 118:593-598, 2009
8. Dores GM, Devesa SS, Curtis RE, et al: Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 119:34-43, 2012
9. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
10. Cogle CR, Craig BM, Rollison DE, et al: Incidence of the myelodysplastic syndromes using a novel claimsbased algorithm: High number of uncaptured cases by cancer registries. Blood 117:7121-7125, 2011
11. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
12. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
13. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer. J Clin Oncol 21: 976-983, 2003
14. Kaplan H, Malmgren J, De Roos AJ: Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: A population-based study. Breast Cancer Res Treat 137:863-867, 2013
15. Hershman D, Neugut AI, Jacobson JS, et al: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99:196-205, 2007
16. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001
17. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
18. Institute of Medicine: Veterans and Agent Orange: Update 2002. http://www.iom.edu/Reports/2003/ Veterans-and-Agent-Orange-Update-2002.aspx
19. Institute of Medicine: Veterans and Agent Orange: Update 2008. http://www.iom.edu/Reports/2009/ Veterans-and-Agent-Orange-Update-2008.aspx
20. Department of Veterans Affairs: Chronic B-cell leukemias and Agent Orange. http://www.publichealth .va.gov/exposures/agentorange/conditions/bcellleukemia. asp
21. Zablotska LB, Bazyka D, Lubin JH, et al: Radiation and the risk of chronic lymphocytic and other leukemias among Chornobyl cleanup workers. Environ Health Perspect 121:59-65, 2013